Comparison

Phenylpiracetam Hydrazide vs Phenylpiracetam

Hydrazide: longer, sharper, lower dose — but more niche. Phenylpiracetam: classic, proven, slightly gentler.

Effectiveness Profile

Phenylpiracetam Hydrazide
Phenylpiracetam

At a Glance

 Phenylpiracetam HydrazidePhenylpiracetam
TypeNootropicNootropic
Legal statusResearchGrey-Market
Half-lifeInferred 4–6 hours (parent fonturacetam 3–5h); subjective duration 6–10h3–5 hours
Preferred routeOralOral
Dose frequencyas-neededas-needed
Beginner dose25–50 mg100–100 mg
Intermediate dose50–100 mg100–200 mg
Advanced dose100–150 mg200–300 mg
Cycle length1–8 wks1–4 wks
Bioavailability100%
Time to peak0.75h1h
Active duration8h6h
StorageRoom temperature, sealed, protected from light and moistureRoom temperature, dry, away from light
PCT requiredNoNo
Ancillaries requiredNoNo
Safe for womenYesYes

Verdict

Phenylpiracetam Hydrazide wins for: sharper focus/tactile stimulation per mg, longer subjective duration (6–10+ hours), less frequent dosing needed, and more potent dopaminergic kick.

Phenylpiracetam wins for: documented safety profile over decades, fewer unknowns around hepatic risk, easier sourcing, and a gentler/comfier ride for broader use-cases. It is also slightly less likely to trigger rapid tolerance for most users.

Pick A or B?

Pick Phenylpiracetam Hydrazide if:

  • A pronounced, stimulant-like focus boost is wanted in a lower dose range (50–75mg).
  • Durability — an 8–10 hour tail — matters more than a short-lived punch.
  • Previous experience with phenylpiracetam left you wanting a stronger/longer effect.
  • The chemistry lab is exploring newer racetam analogues and mechanism tweaks.
  • Single-use or occasional high-output scenarios are prioritized over daily use.

Pick Phenylpiracetam if:

  • Classical racetam effects are preferred, with a robust safety history and fewer unknowns.
  • Proven cognitive or motor drive is needed for exams, heavy training, or demanding work.
  • Sourcing from established nootropic suppliers is important.
  • Minimal hepatotoxicity risk is a deciding factor, especially in longer research blocks.
  • Cholinergic, mild-stimulant effects are the target, rather than full-bore dopaminergic stimulation.